Substance / Medication

Ozenoxacin

Overview

Active Ingredient
ozenoxacin
RxNorm CUI
1994739

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

4 trials linked to this intervention

4
Total Trials
0
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Microbiological profile of ozenoxacin.
Morrissey Ian, Cantón Rafael, Vila Jordi et al. · Future Microbiol · 2019
PMID: 31132895Observational
Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates.
Canton Rafael, Morrissey Ian, Vila Jordi et al. · Future Microbiol · 2018
PMID: 29745242Observational
In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci.
López Y, Tato M, Espinal P et al. · J Antimicrob Chemother · 2015
PMID: 25261416Observational
Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.
Gropper Savion, Albareda Nuria, Chelius Klaus et al. · Future Microbiol · 2014
PMID: 25340832Observational
Ozenoxacin 1% in Pediatric and Adult Patients with Impetigo: A Meta-Analysis of Randomized Trials.
Tuesta Bryam López, Arones-Santayana Camila A, Sáenz Gustavo A Valderrama et al. · J Clin Med · 2025
PMID: 40217608ReviewFull text (PMC)
Potential Role of Ozenoxacin 1% Cream in the Topical Management of Hidradenitis Suppurativa: A Single-centre Experience (44 patients).
Fernández-Crehuet Pablo, Diaz-Ceca Delia, Melgosa Ramos F Javier · Acta Derm Venereol · 2025
PMID: 40607835OtherFull text (PMC)
Ozenoxacin-Induced Contact Dermatitis With Tolerance to Ciprofloxacin.
Otero-Fernández M N, Laffond-Yges E, Castillo-Loja R M et al. · J Investig Allergol Clin Immunol · 2025
PMID: 39535886Other
activity of ozenoxacin againstandclinical isolates recovered in a worldwide multicentre study (2020-2022).
García-Castillo María, Hernández-García Marta, Correa Adriana et al. · JAC Antimicrob Resist · 2024
PMID: 38872714OtherFull text (PMC)
QbD Based Formulation Development and Optimisation of Ozenoxacin Topical Nano-Emulgel and Efficacy Evaluation Using Impetigo Mice Model.
Ramireddy Amarnath Reddy, Behara Dilip Kumar · AAPS PharmSciTech · 2024
PMID: 38649513Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ozenoxacin (substance)
SNOMED CT
763879001
UMLS CUI
C2983945
RxNorm CUI
1994739

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
4
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.